Observational studyActa chirurgiae orthopaedicae et traumatologiae Cechoslovaca2026
[Avascular Necrosis of the Femoral Head after Hodgkin Lymphoma Treatment: Analysis of Risk Factors and Mid-Term Outcomes after Total Hip Replacement].
Observational study in Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the studyTreatment of classical Hodgkin lymphoma (cHL) can be eventually complicated by avascular necrosis of the femoral head (AVN FH). Stages 1 and 2 of AVN FH can be treated conservatively, but stages 3 and 4 are indicated for surgery. In adults, total hip replacement (THR) is the preferred method. The goal of our study was to analyze the risk factors for AVN FH and functional results after THR. MATERIAL AND
methodsThis is a single-center retrospective observational longitudinal study. Patients with AVN FH after previous cHL treatment were included. Basic epidemiological data, time to AVN FH and THR, and complications of hemato-oncological treatment and THRs were recorded. Risk ratios, derived from 2×2 tables and from univariate Cox regression and Kaplan-Meier graphs, were analyzed. Categorical data were evaluated using the Fisher exact test and quantitative data using the Mann-Whitney-Wilcoxon test. Outcomes were measured using the modified Harris Hip Score (MHHS).
resultsThe mean incidence of AVN HF was 1.7 per year (95% CI 1.1-2.2). Patients with THRs tended to be older (p = 0.0424), the highest risk was ≥ 50 years. Mixed cellularity (MC) cHL had a higher risk of THR (log-rank test p = 0.0249) compared to nodular sclerosis (NS) cHL. Clinical stage IIB with massive mediastinal tumor was associated with the lowest risk of THR, p = 0.0348. The mean modified Harris Hip Score (MHHS) was higher in NS compared to MC subtype (85.1 (82.7-87.6) vs. only 75.4 (66.6-84.2), p = 0.0311). Periarticular calcification grade 1 was diagnosed in 84.6% of patients (95% CI 54.6-98.1). Revision surgery with cup and stem replantation was performed in one patient. No infections or cases of deep venous thrombosis were recorded.
conclusionsTHR is a causal treatment of symptomatic AVN FH following cHL treatment. Age ≥ 50 years, MC subtype cHL, and AVN FH stages 3 and 4 were associated with a higher risk of THR. The mean MHHS was fully comparable with THRs for other indications. Higher calcification rates had no impact on the clinical outcome.
Indexed as
Identifiers
42506688What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.